Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat.


Journal

MicroRNA (Shariqah, United Arab Emirates)
ISSN: 2211-5374
Titre abrégé: Microrna
Pays: United Arab Emirates
ID NLM: 101631045

Informations de publication

Date de publication:
2019
Historique:
received: 14 09 2018
revised: 01 11 2018
accepted: 21 12 2018
pubmed: 19 1 2019
medline: 15 7 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

The recent development of drugs that stabilize HIFalpha, called HIF stabilizers, offers a new strategy for treating anemia. Although these drugs are still in clinical trials, misuse for doping has already begun. Identifying the biomarkers of HIF stabilizers would therefore help in detecting this drug misuse by athletes. Our aim was twofold: to determine whether hypoxamiRs, the microRNAs associated with the cellular response to hypoxia, are potential biomarkers of HIF stabilizers in blood and whether the response to treatment with an HIF stabilizer differs from the response to a hypoxic environment. Rats were treated for 6 days with either a placebo or 2mg/kg of Molidustat, an HIF stabilizer, or they were put under hypoxia (10% oxygen) for the same length of time. Plasma samples were analyzed before, during and 48 hours after the treatments. EPO concentration increased significantly in plasma during hypoxia and Molidustat treatment and showed a negative retro-control 2 days after the end of the treatments. On the contrary, circulating levels of VEGF were not modified. Among the hypoxamiRs tested, miR-130a and miR-21 were significantly increased during Molidustat treatment and miR-21 was still increased 48 hours after treatment end. Although using these microRNAs as biomarkers seems unlikely due to other possible factors of regulation, this study provides the first identification of a specific effect of HIF stabilizers on microRNAs. Further investigations are needed to better understand the possible consequences of such regulation.

Sections du résumé

BACKGROUND
The recent development of drugs that stabilize HIFalpha, called HIF stabilizers, offers a new strategy for treating anemia. Although these drugs are still in clinical trials, misuse for doping has already begun. Identifying the biomarkers of HIF stabilizers would therefore help in detecting this drug misuse by athletes.
OBJECTIVE
Our aim was twofold: to determine whether hypoxamiRs, the microRNAs associated with the cellular response to hypoxia, are potential biomarkers of HIF stabilizers in blood and whether the response to treatment with an HIF stabilizer differs from the response to a hypoxic environment.
METHOD
Rats were treated for 6 days with either a placebo or 2mg/kg of Molidustat, an HIF stabilizer, or they were put under hypoxia (10% oxygen) for the same length of time. Plasma samples were analyzed before, during and 48 hours after the treatments.
RESULTS
EPO concentration increased significantly in plasma during hypoxia and Molidustat treatment and showed a negative retro-control 2 days after the end of the treatments. On the contrary, circulating levels of VEGF were not modified. Among the hypoxamiRs tested, miR-130a and miR-21 were significantly increased during Molidustat treatment and miR-21 was still increased 48 hours after treatment end.
CONCLUSION
Although using these microRNAs as biomarkers seems unlikely due to other possible factors of regulation, this study provides the first identification of a specific effect of HIF stabilizers on microRNAs. Further investigations are needed to better understand the possible consequences of such regulation.

Identifiants

pubmed: 30657053
pii: MIRNA-EPUB-95877
doi: 10.2174/2211536608666190117170317
doi:

Substances chimiques

Biomarkers 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
MicroRNAs 0
Pyrazoles 0
Triazoles 0
molidustat 9JH486CZ13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-197

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Alexandre Marchand (A)

Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France.

Ingrid Roulland (I)

Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France.

Florian Semence (F)

Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France.

Kaja Schröder (K)

Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France.

Valérie Domergue (V)

AnimEx Chatenay-Malabry, Plateforme AnimEx IPSIT, Faculte de Pharmacie, Universite Paris-Sud, 5 rue Jean-Baptiste Clement, 92296 Châtenay-Malabry, France.

Michel Audran (M)

Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH